Health Canada Approves Telavancin for Complicated Skin, Skin Structure Infections
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Health Canada Approves Telavancin for Complicated Skin, Skin Structure Infections

NEW YORK -- October 1, 2009 -- Health Canada has approved telavancin (Vibativ) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

The approval is based on 2 large, multinational, double-blind, randomised phase 3 studies (ATLAS 1 and ATLAS 2) designed to compare the efficacy and safety of intravenous telavancin 10 mg/kg once daily versus intravenous vancomycin 1 gm every 12 hours in adult patients with cSSSI caused by Gram-positive bacteria.

A total of 1,867 patients were enrolled and treated, 719 of whom had infections with MRSA. In both of these studies, telavancin achieved its primary endpoint of non-inferiority relative to the standard of care, vancomycin.

The most common adverse reactions occurring in >= 10% of patients treated with telavancin were taste disturbance, nausea, vomiting, and foamy urine.

Serious adverse events were reported in 7% of patients treated with telavancin and most commonly included renal, respiratory, or cardiac events. Serious adverse events were reported in 5% of vancomycin-treated patients, and most commonly included cardiac, respiratory or infectious events.

SOURCE: Theravance, Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities